Showing results (71-80 of 214) with videos related to

Sort By:
Pageof 22
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|October 7, 2004
Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdineErik J Uhlmann, Pablo Tebas, Gregory A Storch, et al.
Current HIV Research|May 28, 2014
Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitantJeffrey S Barrett, Gaurav Bajaj, Jennifer McGuire, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 5, 2008
The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in BotswanaGregory P Bisson, Rudo Nthobatsong, Rameshwari Thakur, et al.
Plos One|April 24, 2008
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular riskPablo Tebas, William Keith Henry, Roy Matining, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2017
The Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture RiskRoger J Bedimo, Beverley Adams-Huet, John Poindexter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 5, 2009
Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cellsGary P Wang, Bruce L Levine, Gwendolyn K Binder, et al.
AIDS Patient Care and Stds|July 21, 2011
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patientsXiaodong Wang, Marta Boffito, Jenny Zhang, et al.
AIDS (London, England)|November 21, 2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIVGrace A McComsey, Michelle A Kendall, Pablo Tebas, et al.
The Journal of Infectious Diseases|May 25, 2011
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202Grace A McComsey, Douglas Kitch, Eric S Daar, et al.
AIDS Research and Human Retroviruses|February 23, 2012
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeksJudith A Aberg, Pablo Tebas, Edgar Turner Overton, et al.
Pageof 22